Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and oblimersen

imatinib mesylate has been researched along with oblimersen in 7 studies

Compound Research Comparison

Studies
(imatinib mesylate)		Trials
(imatinib mesylate)		Recent Studies (post-2010)
(imatinib mesylate)		Studies
(oblimersen)		Trials
(oblimersen)		Recent Studies (post-2010) (oblimersen)
11,4779605,7731954027

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (85.71)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nakajima, A; Ohyashiki, K; Sashida, G; Shimamoto, T; Sumi, M; Tauchi, T1
Tauchi, T1
Kaplow, R1
Grever, MR1
Tan, W1
Bloomfield, CD; Donohue, KA; Feldman, EJ; Hurd, DD; Larson, RA; Odenike, OM; Stone, RM; Westerfelt, P; Wetzler, M1
Aldabagh, B; Joo, J; Yu, SS1

Reviews

5 review(s) available for imatinib mesylate and oblimersen

ArticleYear
[Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2004, Volume: 45, Issue:1

    Topics: Animals; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines; Quinolones; Randomized Controlled Trials as Topic; Thionucleotides

2004
Innovations in antineoplastic therapy.
    The Nursing clinics of North America, 2005, Volume: 40, Issue:1

    Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate

2005
New drugs in acute myeloid leukemia.
    Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:8

    Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Thionucleotides

2003
[Promising new treatment options for metastatic androgen-independent prostate cancer].
    Actas urologicas espanolas, 2007, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides

2007
Merkel cell carcinoma: current status of targeted and future potential for immunotherapies.
    Seminars in cutaneous medicine and surgery, 2014, Volume: 33, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Biomarkers; Carcinoma, Merkel Cell; CD56 Antigen; Electrochemotherapy; Hepatitis A Virus Cellular Receptor 2; Humans; Imatinib Mesylate; Immunotherapy; Immunotherapy, Adoptive; Indazoles; Inhibitor of Apoptosis Proteins; Interferons; Interleukin-12; Interleukin-2; Ipilimumab; Lymphatic Metastasis; Membrane Proteins; Merkel cell polyomavirus; Oligonucleotides, Antisense; Piperazines; Polyomavirus Infections; Prognosis; Programmed Cell Death 1 Receptor; Pyrimidines; Receptors, Somatomedin; Skin Neoplasms; Somatostatin; Sulfonamides; Survivin; Thionucleotides; TOR Serine-Threonine Kinases

2014

Trials

1 trial(s) available for imatinib mesylate and oblimersen

ArticleYear
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Feasibility Studies; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Thionucleotides; Treatment Failure

2008

Other Studies

1 other study(ies) available for imatinib mesylate and oblimersen

ArticleYear
BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Sep-15, Volume: 9, Issue:11

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid; Mice; Mice, Nude; Oligonucleotides, Antisense; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Survival Analysis; Thionucleotides; Time Factors; Transplantation, Heterologous

2003